<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK121283" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK121283/" /><meta name="ncbi_pagename" content="Variegate Porphyria - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Variegate Porphyria - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Variegate Porphyria" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2019/12/12" /><meta name="citation_author" content="Ashwani K Singal" /><meta name="citation_author" content="Karl E Anderson" /><meta name="citation_pmid" content="23409300" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK121283/" /><meta name="citation_keywords" content="Porphyria Variegata" /><meta name="citation_keywords" content="Porphyria Variegata" /><meta name="citation_keywords" content="Protoporphyrinogen oxidase" /><meta name="citation_keywords" content="PPOX" /><meta name="citation_keywords" content="Variegate Porphyria" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Variegate Porphyria" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Ashwani K Singal" /><meta name="DC.Contributor" content="Karl E Anderson" /><meta name="DC.Date" content="2019/12/12" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK121283/" /><meta name="description" content="Variegate porphyria (VP) is both a cutaneous porphyria (with chronic blistering skin lesions) and an acute porphyria (with severe episodic neurovisceral symptoms). The most common manifestation of VP is adult-onset cutaneous blistering lesions (subepidermal vesicles, bullae, and erosions that crust over and heal slowly) of sun-exposed skin, especially the hands and face. Other chronic skin findings include milia, scarring, thickening, and areas of decreased and increased skin pigmentation. Facial hyperpigmentation and hypertrichosis may occur. Cutaneous manifestations may improve in winter and be less prevalent in northern regions and in dark-skinned individuals. Acute neurovisceral symptoms can occur any time after puberty, but less often in the elderly. Acute manifestations are highly variable, but may be similar from episode to episode in a person with recurrent attacks; not all manifestations are present in a single episode; and acute symptoms may become chronic. Symptoms are more common in women than men. The most common manifestations are abdominal pain; constipation; pain in the back, chest, and extremities; anxiety; seizures; and a primarily motor neuropathy resulting in muscle weakness that may progress to quadriparesis and respiratory paralysis. Psychiatric disturbances and autonomic neuropathy can also be observed. Acute attacks may be severe and are potentially fatal." /><meta name="og:title" content="Variegate Porphyria" /><meta name="og:type" content="book" /><meta name="og:description" content="Variegate porphyria (VP) is both a cutaneous porphyria (with chronic blistering skin lesions) and an acute porphyria (with severe episodic neurovisceral symptoms). The most common manifestation of VP is adult-onset cutaneous blistering lesions (subepidermal vesicles, bullae, and erosions that crust over and heal slowly) of sun-exposed skin, especially the hands and face. Other chronic skin findings include milia, scarring, thickening, and areas of decreased and increased skin pigmentation. Facial hyperpigmentation and hypertrichosis may occur. Cutaneous manifestations may improve in winter and be less prevalent in northern regions and in dark-skinned individuals. Acute neurovisceral symptoms can occur any time after puberty, but less often in the elderly. Acute manifestations are highly variable, but may be similar from episode to episode in a person with recurrent attacks; not all manifestations are present in a single episode; and acute symptoms may become chronic. Symptoms are more common in women than men. The most common manifestations are abdominal pain; constipation; pain in the back, chest, and extremities; anxiety; seizures; and a primarily motor neuropathy resulting in muscle weakness that may progress to quadriparesis and respiratory paralysis. Psychiatric disturbances and autonomic neuropathy can also be observed. Acute attacks may be severe and are potentially fatal." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK121283/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/porphyria-var/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK121283/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8A3525E040874100000000025F00C8.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK121283_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK121283_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/vps35-pd/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/eds4/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK121283_"><span class="title" itemprop="name">Variegate Porphyria</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: Porphyria Variegata</div><p class="contrib-group"><span itemprop="author">Ashwani K Singal</span>, MD, MSc and <span itemprop="author">Karl E Anderson</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK121283_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK121283_ai__"><div class="contrib half_rhythm"><span itemprop="author">Ashwani K Singal</span>, MD, MSc<div class="affiliation small">University of South Dakota Sanford School of Medicine<br />Sioux Falls, South Dakota<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.bau@lagniska" class="oemail">ude.bau@lagniska</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Karl E Anderson</span>, MD<div class="affiliation small">University of Texas Medical Branch<br />Galveston, Texas<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.bmtu@osrednak" class="oemail">ude.bmtu@osrednak</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">February 14, 2013</span>; Last Update: <span itemprop="dateModified">December 12, 2019</span>.</p><p><em>Estimated reading time: 28 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="porphyria-var.Summary" itemprop="description"><h2 id="_porphyria-var_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Variegate porphyria (VP) is both a cutaneous porphyria (with chronic blistering skin lesions) and an acute porphyria (with severe episodic neurovisceral symptoms). The most common manifestation of VP is adult-onset cutaneous blistering lesions (subepidermal vesicles, bullae, and erosions that crust over and heal slowly) of sun-exposed skin, especially the hands and face. Other chronic skin findings include milia, scarring, thickening, and areas of decreased and increased skin pigmentation. Facial hyperpigmentation and hypertrichosis may occur. Cutaneous manifestations may improve in winter and be less prevalent in northern regions and in dark-skinned individuals. Acute neurovisceral symptoms can occur any time after puberty, but less often in the elderly. Acute manifestations are highly variable, but may be similar from episode to episode in a person with recurrent attacks; not all manifestations are present in a single episode; and acute symptoms may become chronic. Symptoms are more common in women than men. The most common manifestations are abdominal pain; constipation; pain in the back, chest, and extremities; anxiety; seizures; and a primarily motor neuropathy resulting in muscle weakness that may progress to quadriparesis and respiratory paralysis. Psychiatric disturbances and autonomic neuropathy can also be observed. Acute attacks may be severe and are potentially fatal.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The biochemical diagnosis of VP is established in an individual with elevated urine porphobilinogen (PBG) or porphyrins and a fluorescence peak at ~626 nm on plasma fluorescence scanning; fecal porphyrins are also elevated, with a predominance of coproporphyrin III and protoporphyrin. The molecular diagnosis of VP is established by identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>PPOX</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> The first step in treating either acute neurovisceral attacks or cutaneous manifestations is to identify and remove exacerbating factors (see <i>Agents/circumstances to avoid</i>). Most acute neurovisceral attacks require hospital admission; the presence of seizures, motor neuropathy, and hyponatremia suggest severe disease that ideally should be managed in an ICU. Narcotic analgesics are usually required for pain. Ondansetron or a related drug can be used for nausea and vomiting; phenothiazines can be effective for nausea, agitation, and hallucinations.</p><p>Although mild attacks (without seizures, weakness, or hyponatremia and not requiring narcotics) can sometimes be treated in an outpatient setting with glucose loading, most attacks require treatment with intravenous hemin and in-patient observation for additional supportive management.</p><p>Cutaneous manifestations are best managed by wearing protective clothing and avoiding exposure to sunlight. Symptoms may decrease when exacerbating factors are removed. No treatment is known to be effective in lowering porphyrin levels and reducing cutaneous symptoms. Analgesics may be needed for painful lesions and antibiotics for superimposed infection.</p><p><i>Prevention of primary manifestations:</i> Acute neurovisceral attacks are less likely to occur if exacerbating factors are corrected or avoided. Recurrent premenstrual acute attacks can be prevented with gonadotropin-releasing hormone analogs; weekly or biweekly hemin infusions to prevent frequent noncyclical attacks may be effective, but experience is lacking. Prevention of the skin manifestations requires protection from sunlight.</p><p><i>Surveillance:</i> Liver imaging at six-month intervals beginning at age 50 years in those who have experienced persistent elevations in porphobilinogen or porphyrins may detect early hepatocellular carcinoma.</p><p><i>Agents/circumstances to avoid:</i> Exacerbating factors that should be avoided include drugs such as: barbiturates, sulfonamide antibiotics, griseofulvin, rifampin, most anticonvulsants including phenytoin and carbamazepine, alcohol, ergot alkaloids, metoclopramide, and progestins. Although birth control pills should generally be avoided, low-dose hormonal preparations may be tolerated. Concomitant illnesses should be treated effectively using drugs that are considered safe whenever possible. Updated lists of safe and unsafe drugs are maintained at the websites of the American Porphyria Foundation and the European Porphyria Network.</p><p><i>Evaluation of relatives at risk:</i> At-risk family members can be offered <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for the family-specific <i>PPOX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> to identify those who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> (for the purpose of counseling regarding appropriate use of drugs and avoidance of known exacerbating factors). While biochemical testing, especially plasma fluorescence scanning and fecal porphyrin analysis, is also useful, it is less sensitive than molecular genetic testing.</p><p><i>Pregnancy management:</i> Exacerbations during pregnancy have been treated successfully with heme arginate or heme hydroxide (hematin); while neither preparation has been studied extensively during pregnancy, experience over many years suggests that treatment during pregnancy is unlikely to produce adverse fetal effects.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>VP is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner with reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>. <i>De novo</i> pathogenic variants are rare. Each child of an individual with VP has a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; while offspring who inherit the variant may or may not develop manifestations, most do not. Prenatal testing for pregnancies at increased risk for VP is possible if the pathogenic variant in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member has been identified. Of note, the presence of a <i>PPOX</i> pathogenic variant does not predict whether &#x02013; or at what age &#x02013; an individual will become symptomatic.</p></div></div><div id="porphyria-var.Diagnosis"><h2 id="_porphyria-var_Diagnosis_">Diagnosis</h2><div id="porphyria-var.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Variegate porphyria (VP) <b>should be suspected</b> in individuals with the following clinical findings and initial laboratory findings.</p><p><b>Clinical findings</b></p><ul><li class="half_rhythm"><div><b>Cutaneous manifestations</b> include chronic blistering photosensitivity, most commonly on the backs of the hands. Chronic features include blisters, milia, scarring, thickening, and areas of decreased and increased skin pigmentation. Facial hyperpigmentation and hypertrichosis may occur. The skin lesions are identical to those of <a href="/books/n/gene/porphyria-ct/">porphyria cutanea tarda</a> (PCT) and other blistering cutaneous porphyrias [<a class="bk_pop" href="#porphyria-var.REF.meissner.2003">Meissner et al 2003</a>] (see <a href="#porphyria-var.Differential_Diagnosis">Differential Diagnosis</a>).</div></li><li class="half_rhythm"><div><b>Neurovisceral symptoms</b> most commonly include the following:</div><ul><li class="half_rhythm"><div>Abdominal pain. The pain is typically severe, steady rather than cramping, and diffuse rather than localized. Because the pain is neuropathic rather than inflammatory, abdominal findings are minimal compared to the severity of the pain. Ileus and bladder distension may be present. Acute hepatic porphyrias should be suspected whenever abdominal pain remains unexplained after an initial workup for common causes.</div></li><li class="half_rhythm"><div>Constipation</div></li><li class="half_rhythm"><div>Pain in the back, chest, and extremities</div></li><li class="half_rhythm"><div>Anxiety</div></li><li class="half_rhythm"><div>Seizures</div></li><li class="half_rhythm"><div>Muscle weakness due to a primarily motor neuropathy that usually begins in the proximal upper extremities and may progress to quadriparesis and respiratory paralysis. This is accompanied by pain and sometimes sensory loss. Hyperreflexia may be seen initially, followed by hyporeflexia as motor neuropathy progresses.</div></li><li class="half_rhythm"><div>Hyponatremia, which increases the risk for seizures. It may be a manifestation of hypothalamic involvement and the syndrome of inappropriate antidiuretic hormone secretion [<a class="bk_pop" href="#porphyria-var.REF.anderson.2005.439">Anderson et al 2005</a>].</div></li></ul></li></ul><p><b>Initial biochemical laboratory findings</b>. As VP may present with blistering cutaneous lesions on sun-exposed skin, neurovisceral symptoms or both, initial first-line testing aims to detect all porphyrias that can cause either skin or neurovisceral manifestations (see <a href="#porphyria-var.Differential_Diagnosis">Differential Diagnosis</a>).</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Blistering cutaneous porphyrias</b>
<b>(including VP).</b> When VP or any other blistering cutaneous porphyria is suspected, the recommended initial test is measurement of plasma or urine porphyrins. If elevated, further testing is needed to determine the type of porphyria or whether the porphyrin elevation &#x02013; particularly in urine &#x02013; represents nonspecific porphyrinuria rather than porphyria.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Acute porphyrias (including VP).</b> Measurement of urinary porphobilinogen (PBG)* and total porphyrins. Urine &#x003b4;-aminolevulinic acid (ALA) is often measured at the same time as PBG but this is not necessary for initial screening.</div><div class="half_rhythm">*Note: (1) If an acute porphyria is confirmed by substantial elevation of urinary PBG, treatment can be started, if appropriate, for symptoms of an acute attack (see Management, <a href="#porphyria-var.Treatment_of_Manifestation">Treatment of Manifestations</a>) while further biochemical testing is being performed to determine the type of acute porphyria (see <a href="#porphyria-var.Differential_Diagnosis">Differential Diagnosis</a>). (2) If PBG is normal, total porphyrins and ALA should be measured in the same urine sample, because total porphyrins often remain elevated longer than PBG. In ALA dehydratase-deficiency porphyria (ADP), the rarest type of porphyria, ALA and total porphyrins (but not PBG) are markedly elevated [<a class="bk_pop" href="#porphyria-var.REF.anderson.2005.439">Anderson et al 2005</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Substantial elevation in erythrocyte porphyrins</b> is not consistent with VP, and points to an erythropoietic porphyria as a cause of blistering skin manifestations and elevation of urine and plasma porphyrins. Alternatively, substantial erythrocyte protoporphyrin in an individual with VP may suggest a concurrent condition that elevates zinc protoporphyrin, such as iron deficiency, lead poisoning, or another erythrocyte disorder.</div></li></ul></div><div id="porphyria-var.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><div id="porphyria-var.Biochemical_Diagnosis"><h4>Biochemical Diagnosis</h4><p>When initial biochemical laboratory findings support an acute porphyria (i.e., elevated urine PBG or porphyrins) or a blistering cutaneous porphyria (i.e., elevated plasma or urine porphyrins), further diagnostic biochemical testing (<a class="figpopup" href="/books/NBK121283/table/porphyria-var.T.biochemical_characterist/?report=objectonly" target="object" rid-figpopup="figporphyriavarTbiochemicalcharacterist" rid-ob="figobporphyriavarTbiochemicalcharacterist">Table 1</a>) is required to differentiate VP from other acute and cutaneous porphyrias and from conditions (e.g., liver disease) that cause nonspecific porphyrinuria:</p><ul><li class="half_rhythm"><div><b>Plasma fluorescence scanning</b> can establish or exclude VP when urine PBG is elevated since a fluorescence peak at ~626 nm is not found in any other type of porphyria.</div></li><li class="half_rhythm"><div><b>Fecal porphyrin analysis</b> can differentiate VP, <a href="/books/n/gene/aip/">acute intermittent porphyria</a> (AIP), and <a href="/books/n/gene/hcp/">hereditary coproporphyria</a> (HCP), the only diseases that substantially elevate urine PBG.</div></li><li class="half_rhythm"><div><b>Fecal porphyrin analysis</b> and <b>plasma fluorescence scanning</b> can also reliably distinguish VP from <a href="/books/n/gene/porphyria-ct/">porphyria cutanea tarda</a> (PCT) and other porphyrias that cause blistering skin lesions (see <a href="#porphyria-var.Differential_Diagnosis">Differential Diagnosis</a>).</div></li></ul><div id="porphyria-var.T.biochemical_characterist" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Biochemical Characteristics of Variegate Porphyria (VP)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK121283/table/porphyria-var.T.biochemical_characterist/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__porphyria-var.T.biochemical_characterist_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_porphyria-var.T.biochemical_characterist_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_porphyria-var.T.biochemical_characterist_1_1_1_1" style="text-align:left;vertical-align:middle;">Deficient Enzyme</th><th id="hd_h_porphyria-var.T.biochemical_characterist_1_1_1_2" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Urine PBG and Porphyrins</th><th id="hd_h_porphyria-var.T.biochemical_characterist_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Plasma Fluorescence Scanning</th><th id="hd_h_porphyria-var.T.biochemical_characterist_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Fecal Porphyrins</th></tr><tr><th headers="hd_h_porphyria-var.T.biochemical_characterist_1_1_1_2" id="hd_h_porphyria-var.T.biochemical_characterist_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Active</th><th headers="hd_h_porphyria-var.T.biochemical_characterist_1_1_1_2" id="hd_h_porphyria-var.T.biochemical_characterist_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Asx</th><th headers="hd_h_porphyria-var.T.biochemical_characterist_1_1_1_3" id="hd_h_porphyria-var.T.biochemical_characterist_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Active</th><th headers="hd_h_porphyria-var.T.biochemical_characterist_1_1_1_3" id="hd_h_porphyria-var.T.biochemical_characterist_1_1_2_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Asx</th><th headers="hd_h_porphyria-var.T.biochemical_characterist_1_1_1_4" id="hd_h_porphyria-var.T.biochemical_characterist_1_1_2_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Active</th><th headers="hd_h_porphyria-var.T.biochemical_characterist_1_1_1_4" id="hd_h_porphyria-var.T.biochemical_characterist_1_1_2_6" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Asx</th></tr></thead><tbody><tr><td headers="hd_h_porphyria-var.T.biochemical_characterist_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">PPOX&#x000a0;<sup>1,&#x000a0;2</sup></td><td headers="hd_h_porphyria-var.T.biochemical_characterist_1_1_1_2 hd_h_porphyria-var.T.biochemical_characterist_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191; PBG, ALA &#x00026; total porphyrins&#x000a0;<sup>3,&#x000a0;4,&#x000a0;5</sup></td><td headers="hd_h_porphyria-var.T.biochemical_characterist_1_1_1_2 hd_h_porphyria-var.T.biochemical_characterist_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191; or NI PBG, ALA &#x00026; total porphyrins&#x000a0;<sup>6</sup></td><td headers="hd_h_porphyria-var.T.biochemical_characterist_1_1_1_3 hd_h_porphyria-var.T.biochemical_characterist_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191;; see footnote 8</td><td headers="hd_h_porphyria-var.T.biochemical_characterist_1_1_1_3 hd_h_porphyria-var.T.biochemical_characterist_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191;; see footnote 8</td><td headers="hd_h_porphyria-var.T.biochemical_characterist_1_1_1_4 hd_h_porphyria-var.T.biochemical_characterist_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 7</td><td headers="hd_h_porphyria-var.T.biochemical_characterist_1_1_1_4 hd_h_porphyria-var.T.biochemical_characterist_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 8</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Active = symptomatic <i>PPOX</i> heterozygotes; ALA = &#x003b4;-aminolevulinic acid; Asx = asymptomatic <i>PPOX</i> heterozygotes; NI = not increased; PBG = porphobilinogen; PPOX = protoporphyrinogen oxidase</p></div></dd><dt>1. </dt><dd><div id="porphyria-var.TF.1.1"><p class="no_margin">This enzyme oxidizes protoporphyrinogen to protoporphyrin and its deficiency leads to accumulation of protoporphyrinogen in the liver, which subsequently is autoxidized to protoporphyrin.</p></div></dd><dt>2. </dt><dd><div id="porphyria-var.TF.1.2"><p class="no_margin">The enzyme assay is not needed for diagnostic purposes and is not widely available.</p></div></dd><dt>3. </dt><dd><div id="porphyria-var.TF.1.3"><p class="no_margin">PBG elevation should be detected by a quantitative method such as that described by <a class="bk_pop" href="#porphyria-var.REF.mauzerall.1956.435">Mauzerall &#x00026; Granick [1956]</a> which also measures ALA or mass spectrometry. Results of qualitative methods such as the Watson-Schwartz and Hoesch tests, which are considered obsolete, should be confirmed on the same sample by a quantitative method. ALA is less elevated than PBG. Note: ALA is elevated in <i>ALAD</i> porphyria (ADP), in which PBG is normal or only slightly increased.</p></div></dd><dt>4. </dt><dd><div id="porphyria-var.TF.1.4"><p class="no_margin">Active VP is suggested by a quantitative PBG that is substantially elevated.</p></div></dd><dt>5. </dt><dd><div id="porphyria-var.TF.1.5"><p class="no_margin">For screening, it is also useful to measure total porphyrins in the same urine sample, since levels of PBG can be less elevated in VP and HCP than in AIP and decrease to normal more rapidly. Note: Unlike a substantial increase in PBG, a substantial increase in urinary porphyrins does not indicate porphyria, as urinary porphyrins are increased in many other medical conditions, especially when the hepatobiliary system or bone marrow is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</p></div></dd><dt>6. </dt><dd><div id="porphyria-var.TF.1.6"><p class="no_margin">PBG and total porphyrins may not be elevated in persons whose symptoms have resolved. If an acute porphyria is suspected to have caused past symptoms, full biochemical testing to include urinary ALA, PBG, and porphyrins, fecal porphyrins, and plasma porphyrins may be indicated.</p></div></dd><dt>7. </dt><dd><div id="porphyria-var.TF.1.7"><p class="no_margin">Fecal porphyrins are markedly elevated in HCP and VP, whereas in AIP there is little or no elevation. The pattern of fecal porphyrins differentiates HCP and VP, with marked predominance of coproporphyrin III in HCP, and roughly equal elevations of coproporphyrin III and protoporphyrin in VP.</p></div></dd><dt>8. </dt><dd><div id="porphyria-var.TF.1.8"><p class="no_margin">A fluorescence scan of diluted plasma at neutral pH provides a fluorescence peak at wavelength ~626 nm in VP that is highly sensitive and specific for this porphyria [<a class="bk_pop" href="#porphyria-var.REF.pohfitzpatrick.1980.543">Poh-Fitzpatrick 1980</a>]. This is the most sensitive biochemical method for establishing VP in the absence of symptoms. Fecal porphyrin analysis is somewhat less sensitive than plasma fluorescence scanning.</p></div></dd></dl></div></div></div></div><div id="porphyria-var.Molecular_Diagnosis"><h4>Molecular Diagnosis</h4><p>Identification of the causative <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is now considered standard of care in VP and other acute porphyrias to confirm the diagnosis and inform <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (see <a href="#porphyria-var.Genetic_Counseling">Genetic Counseling</a>) (see <b>Option 1</b> and <b>Option 2</b>).</p><p><b>Option 1.</b> It is generally preferred to establish the biochemical diagnosis of VP first, followed by confirmatory single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> (<i>PPOX</i>) testing. However, a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> (<i>HMBS</i>, <i>CPOX</i>, <i>PPOX</i>) can be used to establish the diagnosis when biochemical testing (e.g., substantial PBG elevation) indicates a diagnosis of AIP, HCP, or VP or when the individual to be tested has become asymptomatic and biochemical abnormalities are absent or nonspecific.</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing of</b>
<i>PPOX</i> is generally recommended after a diagnosis of VP is established biochemically. Sequence analysis detects small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-gene deletions/duplications are not detected. Standard practice is to perform <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> first. If no <i>PPOX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found in an individual with biochemically proven VP, perform gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> to detect intragenic deletions or duplications.</div><div class="half_rhythm">Note: When VP is established biochemically in members of the Afrikaner population of South Africa, it is reasonable to consider targeted analysis for the <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a>, <a class="figpopup" href="/books/NBK121283/table/porphyria-var.T.notable_ppox_pathogenic/?report=objectonly" target="object" rid-figpopup="figporphyriavarTnotableppoxpathogenic" rid-ob="figobporphyriavarTnotableppoxpathogenic">p.Arg59Trp</a>, observed in about 95% of persons with variegate porphyria in that population [<a class="bk_pop" href="#porphyria-var.REF.dean.1971">Dean 1971</a>, <a class="bk_pop" href="#porphyria-var.REF.meissner.1996.95">Meissner et al 1996</a>]. See <a class="figpopup" href="/books/NBK121283/table/porphyria-var.T.notable_ppox_pathogenic/?report=objectonly" target="object" rid-figpopup="figporphyriavarTnotableppoxpathogenic" rid-ob="figobporphyriavarTnotableppoxpathogenic">Table 4. Notable <i>PPOX</i> Pathogenic Variants</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>An acute porphyria <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>PPOX</i> and other genes of interest (particularly <i>HMBS</i> and <i>CPOX</i>; see <a href="#porphyria-var.Differential_Diagnosis">Differential Diagnosis</a>) is most likely to identify the genetic cause of symptoms and PBG elevation at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</div><div class="half_rhythm"><i>ALAD</i>, the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding the enzyme ALA dehydratase (which is deficient in ALA dehydratase-deficiency porphyria) may also be included in the panel, but is only relevant when ALA and porphyrins (but not PBG) are elevated.</div><div class="half_rhythm">Note: (1) The diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> may vary by laboratory and is likely to change over time. (2) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><p><b>Option 2.</b> Genomic testing is not recommended for initial diagnosis of acute porphyrias. However, when <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing obtained as part of a search for the cause of unexplained symptoms identifies <i>HMBS</i>, <i>CPOX</i>, or <i>PPOX</i> pathogenic variants or variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, biochemical testing that documents elevations in PBG and porphyrins confirms porphyria as the cause of the symptoms &#x02013; and confirms the diagnosis of VP.</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="porphyria-var.T.molecular_genetic_testin" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Variegate Porphyria</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK121283/table/porphyria-var.T.molecular_genetic_testin/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__porphyria-var.T.molecular_genetic_testin_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_porphyria-var.T.molecular_genetic_testin_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_porphyria-var.T.molecular_genetic_testin_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_porphyria-var.T.molecular_genetic_testin_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_porphyria-var.T.molecular_genetic_testin_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>PPOX</i></td><td headers="hd_h_porphyria-var.T.molecular_genetic_testin_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_porphyria-var.T.molecular_genetic_testin_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">96%-100%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_porphyria-var.T.molecular_genetic_testin_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_porphyria-var.T.molecular_genetic_testin_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_porphyria-var.T.molecular_genetic_testin_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis for pathogenic variants</td><td headers="hd_h_porphyria-var.T.molecular_genetic_testin_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="figpopup" href="/books/NBK121283/table/porphyria-var.T.notable_ppox_pathogenic/?report=objectonly" target="object" rid-figpopup="figporphyriavarTnotableppoxpathogenic" rid-ob="figobporphyriavarTnotableppoxpathogenic">p.Arg59Trp</a>&#x000a0;<sup>7</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="porphyria-var.TF.2.1"><p class="no_margin">See <a href="/books/NBK121283/#porphyria-var.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="porphyria-var.TF.2.2"><p class="no_margin">See <a href="#porphyria-var.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="porphyria-var.TF.2.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="porphyria-var.TF.2.4"><p class="no_margin"><a class="bk_pop" href="#porphyria-var.REF.whatley.2009.1406">Whatley et al [2009]</a></p></div></dd><dt>5. </dt><dd><div id="porphyria-var.TF.2.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="porphyria-var.TF.2.6"><p class="no_margin">Multiexon deletions of <i>PPOX</i> have been reported [<a class="bk_pop" href="#porphyria-var.REF.barbaro.2013.13">Barbaro et al 2013</a>]; however, no data on detection rate of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> are available.</p></div></dd><dt>7. </dt><dd><div id="porphyria-var.TF.2.7"><p class="no_margin">VP is especially common in South Africa, where the <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> <a class="figpopup" href="/books/NBK121283/table/porphyria-var.T.notable_ppox_pathogenic/?report=objectonly" target="object" rid-figpopup="figporphyriavarTnotableppoxpathogenic" rid-ob="figobporphyriavarTnotableppoxpathogenic">p.Arg59Trp</a> [<a class="bk_pop" href="#porphyria-var.REF.dean.1971">Dean 1971</a>] accounts for about 95% of cases [<a class="bk_pop" href="#porphyria-var.REF.meissner.1996.95">Meissner et al 1996</a>].</p></div></dd></dl></div></div></div></div></div></div><div id="porphyria-var.Clinical_Characteristics"><h2 id="_porphyria-var_Clinical_Characteristics_">Clinical Characteristics</h2><div id="porphyria-var.Clinical_Description"><h3>Clinical Description</h3><p>Variegate porphyria (VP) is classified as both a cutaneous and an acute porphyria. It can present with chronic blistering cutaneous manifestations and/or acute attacks of neurovisceral manifestations that may become chronic.</p><p><b>Cutaneous manifestations.</b> Chronic blistering photosensitivity, typically on the backs of the hands, is the most common manifestation of VP. The lesions result from sun exposure that activates porphyrins and makes the skin fragile and prone to blister formation. Lesions are located on sun-exposed areas, especially the dorsal aspects of the hands and less frequently the face, neck, ears, and lower extremities. Because sun-induced damage is not acute, the role of sunlight is often not recognized. Cutaneous manifestations may improve in winter and be less prevalent in northern regions and in dark-skinned individuals.</p><p>These and other manifestations of VP appear typically in adulthood and rarely before puberty.</p><p>The subepidermal vesicles, bullae, and erosions crust over and heal slowly. When blisters rupture they may become infected and painful.</p><p>Other chronic skin findings include milia, scarring, thickening, and areas of decreased and increased skin pigmentation. Facial hyperpigmentation and hypertrichosis may occur.</p><p>The skin manifestations are identical to those seen in <a href="/books/n/gene/porphyria-ct/">porphyria cutanea tarda</a> (PCT) and <a href="/books/n/gene/hcp/">hereditary coproporphyria</a> (HCP), and less severe than those seen in <a href="/books/n/gene/cep/">congenital erythropoietic porphyria</a> (CEP) and <a href="/books/n/gene/hep/">hepatoerythropoietic porphyria</a> (HEP). They contrast with the acute non-blistering photocutaneous manifestations of <a href="/books/n/gene/epp-ar/">erythropoietic protoporphyria</a> (EPP) (see <a class="figpopup" href="/books/NBK121283/table/porphyria-var.T.classification_of_the_he/?report=objectonly" target="object" rid-figpopup="figporphyriavarTclassificationofthehe" rid-ob="figobporphyriavarTclassificationofthehe">Table 3</a>).</p><p>Of note, the great majority of individuals who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>PPOX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> are asymptomatic and are unlikely to be recognized unless they are screened for VP based on a family history of VP (see <a href="#porphyria-var.Genetic_Counseling">Genetic Counseling</a>). In South Africa the frequency of acute attacks has decreased in recent decades. This may be due to less common use of harmful drugs such as barbiturates and sulfonamide antibiotics in clinical practice and perhaps better case recognition and better dissemination of information on how to avoid future attacks. VP now more commonly presents in South Africa with cutaneous rather than acute manifestations [<a class="bk_pop" href="#porphyria-var.REF.meissner.2003">Meissner et al 2003</a>, <a class="bk_pop" href="#porphyria-var.REF.anderson.2005.439">Anderson et al 2005</a>, <a class="bk_pop" href="#porphyria-var.REF.hift.2005.48">Hift &#x00026; Meissner 2005</a>].</p><p><b>Neurovisceral symptoms</b> can occur at any age after puberty as acute attacks, but may become chronic. Symptoms are more common in women than men, and occur less often in the elderly. The frequency and severity of attacks vary considerably and are determined, in part, by exacerbating factors such as certain drugs, hormones, and nutritional deficits [<a class="bk_pop" href="#porphyria-var.REF.anderson.2005.439">Anderson et al 2005</a>]. The proportion of persons <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>PPOX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> who experience acute attacks decreased from about 30%-40% in the 1980s to 5%-10% in 2005 [<a class="bk_pop" href="#porphyria-var.REF.hift.2005.48">Hift &#x00026; Meissner 2005</a>].</p><p>The neurovisceral symptoms are identical to those in the other acute porphyrias (see <a href="#porphyria-var.Differential_Diagnosis">Differential Diagnosis</a>).</p><p>Acute manifestations vary. The most common symptoms are abdominal pain; nausea and vomiting; constipation; pain in the back, chest, and extremities; anxiety; seizures; and a predominantly motor peripheral neuropathy resulting in muscle weakness that may progress to quadriparesis and respiratory paralysis [<a class="bk_pop" href="#porphyria-var.REF.kauppinen.1992.1">Kauppinen &#x00026; Mustajoki 1992</a>, <a class="bk_pop" href="#porphyria-var.REF.meissner.2003">Meissner et al 2003</a>, <a class="bk_pop" href="#porphyria-var.REF.anderson.2005.439">Anderson et al 2005</a>, <a class="bk_pop" href="#porphyria-var.REF.hift.2005.48">Hift &#x00026; Meissner 2005</a>]. Psychiatric disturbances and autonomic neuropathy can also be observed. Not all symptoms are present in a single episode and symptoms can vary from episode to episode; however, recurrent attacks are often similar. Acute attacks may be severe and are potentially fatal, but on average are less frequent and less severe than those observed in <a href="/books/n/gene/aip/">acute intermittent porphyria</a> (AIP) [<a class="bk_pop" href="#porphyria-var.REF.hift.2005.48">Hift &#x00026; Meissner 2005</a>].</p><p>Motor neuropathy usually manifests initially as proximal upper-extremity muscle weakness and can be difficult to detect. Hyperreflexia may be seen initially, followed by hyporeflexia as the motor neuropathy progresses. The motor neuropathy may be accompanied by sensory loss. Note: Motor neuropathy due to acute porphyrias is accompanied by little or no elevation of cerebrospinal fluid protein, which helps to differentiate it from the Landry Guillain-Barr&#x000e9; syndrome [<a class="bk_pop" href="#porphyria-var.REF.anderson.2005.439">Anderson et al 2005</a>].</p><p>Because abdominal pain is neuropathic rather than inflammatory, abdominal findings are minimal compared to the severity of the pain. Ileus and bladder distension may be present.</p><p>An acute attack can be fatal in the presence of severe manifestations including neuropathy, seizures, and respiratory compromise. If managed properly, the outcome of an acute attack is generally good. Even severe motor neuropathy is reversible with recovery over a variable period of months and sometimes over several years.</p><p>Factors that predispose to acute attacks that are often identified include exposure to a harmful drug, alcohol, reduced dietary intake, or stress from an infection or other illness. Most harmful drugs are known to be inducers of hepatic &#x003b4;-aminolevulinic acid synthase (ALAS) and hepatic cytochrome P450 enzymes (see <a href="#porphyria-var.AgentsCircumstances_to_Avo">Agents/Circumstances to Avoid</a>). Pregnancy is usually well tolerated but can precipitate acute attacks in some women.</p><p>Physical findings such as tachycardia, hypertension, restlessness, and agitation result from autonomic neuropathy and increased circulating catecholamines.</p><p>Chronic pain may be a manifestation of VP and other acute porphyrias. Depression may be more difficult to link to the disease. Chronic pain and depression may become important management issues.</p><p>Chronic liver abnormalities, particularly mild elevation of serum transaminases, are common. Risks for development of hepatocellular carcinoma and chronic renal disease are increased in VP (as well as in <a href="/books/n/gene/aip/">AIP</a> and <a href="/books/n/gene/hcp/">HCP</a>). Hepatocellular carcinoma may develop, especially after age 50 years in persons with persistent elevations in porphobilinogen and porphyrins.</p><p>Note: The speculation that King George III (and perhaps others in the British royal family) had VP has been discounted [<a class="bk_pop" href="#porphyria-var.REF.peters.2011.261">Peters 2011</a>].</p></div><div id="porphyria-var.GenotypePhenotype_Correlat"><h3>Genotype-Phenotype Correlations</h3><p><i>PPOX</i> pathogenic variants are generally severe and result in little or no enzyme activity; the residual approximately half-normal enzyme activity is a product of the normal <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>. Therefore, different pathogenic variants are not associated with differences in disease severity [<a class="bk_pop" href="#porphyria-var.REF.whatley.1999.984">Whatley et al 1999</a>, <a class="bk_pop" href="#porphyria-var.REF.whatley.2009.1406">Whatley et al 2009</a>].</p><p><b>Double heterozygosity for pathogenic variants in two different genes in the heme biosynthetic pathway.</b> A patient with cutaneous manifestations initially diagnosed as HCP was found to be a double <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> for pathogenic variants in <i>PPOX</i> and <i>CPOX</i> after other family members were found to have clinical and biochemical features of VP [<a class="bk_pop" href="#porphyria-var.REF.van_tuyll_van_serooskerken.2011.2249">van Tuyll van Serooskerken et al 2011</a>]. The phenotypes of such rare double heterozygotes are not necessarily more severe than the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> associated with heterozygosity for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in one <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> alone, suggesting that individuals who are doubly <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for pathogenic variants in genes causing two different types of acute porphyria may be more common than has been assumed.</p><p>Note: Typically double heterozygosity is suspected because of unusual biochemical patterns, and thus is unlikely to be recognized without comprehensive biochemical testing [<a class="bk_pop" href="#porphyria-var.REF.van_tuyll_van_serooskerken.2011.2249">van Tuyll van Serooskerken et al 2011</a>], which then identifies a need for additional <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div id="porphyria-var.Penetrance"><h3>Penetrance</h3><p><i>PPOX</i> pathogenic variants that result in VP produce little or no functional enzyme; the approximately 50% of normal residual enzyme activity results primarily from the normal <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>. Penetrance is low, but may be increased by factors that increase the demand for hepatic heme synthesis. Penetrance is likely influenced by modifying genes that remain to be identified.</p></div><div id="porphyria-var.Nomenclature"><h3>Nomenclature</h3><p>Variegate porphyria (VP) and <a href="/books/n/gene/hcp/">hereditary coproporphyria</a> (HCP) were sometimes referred to as mixed porphyria, which is now an obsolete term.</p><p>VP has also been referred to as South African acute porphyria or protocoproporphyria.</p><p>In the past, <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> <a href="/books/n/gene/porphyria-ct/">porphyria cutanea tarda</a> (PCT) may not have been clearly differentiated from VP in some instances.</p></div><div id="porphyria-var.Prevalence"><h3>Prevalence</h3><p>It is estimated that in the South African population three individuals per 1,000 are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the <i>PPOX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> <a class="figpopup" href="/books/NBK121283/table/porphyria-var.T.notable_ppox_pathogenic/?report=objectonly" target="object" rid-figpopup="figporphyriavarTnotableppoxpathogenic" rid-ob="figobporphyriavarTnotableppoxpathogenic">p.Arg59Trp</a> [<a class="bk_pop" href="#porphyria-var.REF.meissner.1996.95">Meissner et al 1996</a>, <a class="bk_pop" href="#porphyria-var.REF.meissner.2003">Meissner et al 2003</a>].</p><p>The prevalence of VP with present or past symptoms in Europe is about half that for acute intermittent porphyria (<a href="/books/n/gene/aip/">AIP</a>), and has been estimated at 3.2:1,000,000 [<a class="bk_pop" href="#porphyria-var.REF.elder.2013.849">Elder et al 2013</a>].</p></div></div><div id="porphyria-var.Genetically_Related_Alleli"><h2 id="_porphyria-var_Genetically_Related_Alleli_">Genetically Related (Allelic) Disorders</h2><p><b>Individuals with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>PPOX</i> pathogenic variants</b> (i.e., homozygotes or compound heterozygotes) have been described on rare occasions [<a class="bk_pop" href="#porphyria-var.REF.frank.1998.452">Frank et al 1998</a>, <a class="bk_pop" href="#porphyria-var.REF.pinder.2013.737">Pinder et al 2013</a>]. In childhood they manifest neurologic findings including intellectual disability and/or seizures and cutaneous manifestations only. In these individuals one or both alleles must produce some PPOX enzyme.</p></div><div id="porphyria-var.Differential_Diagnosis"><h2 id="_porphyria-var_Differential_Diagnosis_">Differential Diagnosis</h2><p>The genetic porphyrias comprise a group of distinct diseases, each resulting from alteration of a specific step in the heme synthesis pathway that results in characteristic patterns of accumulation of pathway intermediates (<a class="figpopup" href="/books/NBK121283/figure/porphyria-var.F1/?report=objectonly" target="object" rid-figpopup="figporphyriavarF1" rid-ob="figobporphyriavarF1">Figure 1</a>).</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figporphyriavarF1" co-legend-rid="figlgndporphyriavarF1"><a href="/books/NBK121283/figure/porphyria-var.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figporphyriavarF1" rid-ob="figobporphyriavarF1"><img class="small-thumb" src="/books/NBK121283/bin/porphyria-var-Image001.gif" src-large="/books/NBK121283/bin/porphyria-var-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndporphyriavarF1"><h4 id="porphyria-var.F1"><a href="/books/NBK121283/figure/porphyria-var.F1/?report=objectonly" target="object" rid-ob="figobporphyriavarF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Excretion profile of the hepatic porphyrias Profile of heme precursor excretion for the types of hepatic porphyria. The pathway of heme synthesis (arrows) is served by a series of enzymes (boxes). Pathogenic variants that decrease the function of a particular <a href="/books/NBK121283/figure/porphyria-var.F1/?report=objectonly" target="object" rid-ob="figobporphyriavarF1">(more...)</a></p></div></div><p>In <a class="figpopup" href="/books/NBK121283/table/porphyria-var.T.classification_of_the_he/?report=objectonly" target="object" rid-figpopup="figporphyriavarTclassificationofthehe" rid-ob="figobporphyriavarTclassificationofthehe">Table 3</a> the porphyrias are grouped by their principal clinical manifestations (neurovisceral or cutaneous) and the tissue origin of the excess production of pathway intermediates: liver (i.e., hepatic); or bone marrow (i.e., erythropoietic).</p><p>Porphyrias with neurologic manifestations are considered acute because the symptoms usually occur as discrete, severe episodes, which may be induced by endogenous hormones, drugs and dietary changes; they are difficult to diagnose due to their rarity and the nonspecific nature of symptoms, even when severe. The four acute porphyrias (often referred to as acute hepatic porphyrias) are: ALA dehydratase deficiency porphyria (ADP), <a href="/books/n/gene/aip/">acute intermittent porphyria</a> (AIP), <a href="/books/n/gene/hcp/">hereditary coproporphyria</a> (HCP), and variegate porphyria (VP). Only a few individuals with ADP have been reported in the world literature, and whether this porphyria is hepatic, erythropoietic, or both is uncertain.</p><p>Porphyrias with cutaneous manifestations include those causing chronic blistering skin lesions (i.e., VP as well as <a href="/books/n/gene/porphyria-ct/">porphyria cutanea tarda</a> [PCT], HCP, <a href="/books/n/gene/cep/">congenital erythropoietic porphyria</a> [CEP], and <a href="/books/n/gene/hep/">hepatoerythropoietic porphyria</a> [HEP]) or acute non-blistering photosensitivity (i.e., <a href="/books/n/gene/epp-ar/">EPP</a> and <a href="/books/n/gene/epp-xl/">XLP</a>).</p><div id="porphyria-var.T.classification_of_the_he" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Classification of the Hereditary Porphyrias</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK121283/table/porphyria-var.T.classification_of_the_he/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__porphyria-var.T.classification_of_the_he_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_1" rowspan="2" colspan="2" scope="colgroup" headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_1" style="text-align:left;vertical-align:middle;">Type of Porphyria</th><th id="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;">Findings</th></tr><tr><th headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_4" id="hd_h_porphyria-var.T.classification_of_the_he_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Neurovisceral&#x000a0;<sup>1</sup></th><th headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_4" id="hd_h_porphyria-var.T.classification_of_the_he_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Photocutaneous</th></tr></thead><tbody><tr><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_1" rowspan="6" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Hepatic</b></td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ADP</td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ALAD</i></td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_4 hd_h_porphyria-var.T.classification_of_the_he_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_4 hd_h_porphyria-var.T.classification_of_the_he_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td></tr><tr><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/aip/">AIP</a></td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HMBS</i></td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_4 hd_h_porphyria-var.T.classification_of_the_he_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_4 hd_h_porphyria-var.T.classification_of_the_he_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td></tr><tr><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/hcp/">HCP</a></td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CPOX</i></td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_4 hd_h_porphyria-var.T.classification_of_the_he_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_4 hd_h_porphyria-var.T.classification_of_the_he_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td></tr><tr><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/porphyria-ct/">PCT type II</a>&#x000a0;<sup>2</sup></td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><i>UROD</i></td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_4 hd_h_porphyria-var.T.classification_of_the_he_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_4 hd_h_porphyria-var.T.classification_of_the_he_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td></tr><tr><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/hep/">HEP</a>&#x000a0;<sup>3</sup></td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_4 hd_h_porphyria-var.T.classification_of_the_he_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_4 hd_h_porphyria-var.T.classification_of_the_he_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td></tr><tr><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">VP</td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PPOX</i></td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_4 hd_h_porphyria-var.T.classification_of_the_he_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_4 hd_h_porphyria-var.T.classification_of_the_he_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td></tr><tr><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_1" rowspan="4" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Erythropoietic</b></td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/cep/">CEP</a>&#x000a0;<sup>4</sup></td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>UROS</i></td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_4 hd_h_porphyria-var.T.classification_of_the_he_1_1_2_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_4 hd_h_porphyria-var.T.classification_of_the_he_1_1_2_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">+</td></tr><tr><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>GATA1</i></td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XL</td></tr><tr><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/epp-ar/">EPP</a></td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FECH</i></td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_4 hd_h_porphyria-var.T.classification_of_the_he_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_4 hd_h_porphyria-var.T.classification_of_the_he_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+&#x000a0;<sup>5</sup></td></tr><tr><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/epp-xl/">XLP</a></td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ALAS2</i></td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XL</td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_4 hd_h_porphyria-var.T.classification_of_the_he_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_porphyria-var.T.classification_of_the_he_1_1_1_4 hd_h_porphyria-var.T.classification_of_the_he_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+&#x000a0;<sup>5</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">0 = no symptoms; + = mild to severe symptoms; AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; ADP = ALA dehydratase-deficiency porphyria; AIP = acute intermittent porphyria; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; CEP = <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> erythropoietic porphyria; EPP = erythropoietic protoporphyria; HCP = hereditary coproporphyria; HEP = hepatoerythropoietic porphyria; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; PCT = porphyria cutanea tarda; VP = variegate porphyria; XL = <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a>; XLP = X-linked protoporphyria</p></div></dd><dt>1. </dt><dd><div id="porphyria-var.TF.3.1"><p class="no_margin">Porphyrias with neurovisceral manifestations have been considered "acute" because symptoms usually occur acutely as discrete, severe episodes; however, some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals develop chronic manifestations.</p></div></dd><dt>2. </dt><dd><div id="porphyria-var.TF.3.2"><p class="no_margin">PCT is primarily an acquired, iron-related disorder with multiple susceptibility factors. Approximately 20% of individuals with PCT have a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>UROD,</i> the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding uroporphyrinogen decarboxylase, which is referred to as PCT type II (<a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a>). In PCT type I (<a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a>, ~80% of individuals with PCT) <i>UROD</i> is normal. Type III (rare) is also familial due to inherited factors other than <i>UROD</i> variants. Types I-III are clinically indistinguishable and respond to the same treatments.</p></div></dd><dt>3. </dt><dd><div id="porphyria-var.TF.3.3"><p class="no_margin">HEP is the <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> form of PCT type II (<a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a>).</p></div></dd><dt>4. </dt><dd><div id="porphyria-var.TF.3.4"><p class="no_margin">CEP is most commonly associated with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>UROS</i> pathogenic variants and inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner; on rare occasion, CEP is caused by mutation of <i>GATA1</i> and inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner.</p></div></dd><dt>5. </dt><dd><div id="porphyria-var.TF.3.5"><p class="no_margin">Photocutaneous manifestations of EPP and XLP are acute and non-blistering, in contrast to the chronic blistering in the other cutaneous porphyrias (including VP).</p></div></dd></dl></div></div></div><p><b>Acute neurologic porphyrias.</b> The acute neurovisceral symptoms of VP are identical to those of the other acute porphyrias. VP can be differentiated from AIP and HCP by plasma fluorescence scanning and fecal porphyrin analysis (<a class="figpopup" href="/books/NBK121283/table/porphyria-var.T.biochemical_characterist/?report=objectonly" target="object" rid-figpopup="figporphyriavarTbiochemicalcharacterist" rid-ob="figobporphyriavarTbiochemicalcharacterist">Table 1</a>) or by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (<a class="figpopup" href="/books/NBK121283/table/porphyria-var.T.molecular_genetic_testin/?report=objectonly" target="object" rid-figpopup="figporphyriavarTmoleculargenetictestin" rid-ob="figobporphyriavarTmoleculargenetictestin">Table 2</a>).</p><p>In individuals with progressive weakness due to the motor neuropathy caused by one of the acute porphyrias (AIP, VP, HCP, and ADP), the entity most likely to be considered is acute ascending polyneuropathy, the Landry Guillain-Barr&#x000e9; syndrome.</p><ul><li class="half_rhythm"><div>Abdominal pain, constipation, and tachycardia usually accompany the acute neurologic illness in the acute porphyrias but not in Landry Guillain-Barr&#x000e9; syndrome.</div></li><li class="half_rhythm"><div>CSF protein is usually normal in the acute porphyrias, but usually elevated in Landry Guillain-Barr&#x000e9; syndrome.</div></li><li class="half_rhythm"><div>Most importantly, urinary PBG is markedly elevated in the acute porphyrias especially when symptoms are present, but normal in Landry Guillain-Barr&#x000e9; syndrome.</div></li></ul><p><b>Chronic blistering photocutaneous porphyrias.</b> VP can be readily differentiated from the following conditions by biochemical testing and ultimately confirmed by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p><ul><li class="half_rhythm"><div>The blistering skin lesions of <a href="/books/n/gene/porphyria-ct/">porphyria cutanea tarda</a> (PCT), the most common human porphyria, are identical to those of VP. Because PCT is much more common than VP, patients with VP are often misdiagnosed as having PCT. Because treatment for PCT is not effective in VP, it is important to differentiate these disorders before initiating treatment.</div></li><li class="half_rhythm"><div><a href="/books/n/gene/hcp/">HCP</a> is associated with such skin manifestations much less commonly than VP.</div></li><li class="half_rhythm"><div>Blistering skin manifestations occur in <a href="/books/n/gene/aip/">AIP</a> only when concurrent end-stage renal disease impairs porphyrin excretion, and thus increases plasma porphyrin levels.</div></li><li class="half_rhythm"><div>Cutaneous manifestations of <a href="/books/n/gene/cep/">CEP</a> and <a href="/books/n/gene/hep/">HEP</a> are also chronic and blistering but usually more severe than those of VP because circulating porphyrin levels are usually much higher (often by an order of magnitude) than in PCT and VP. Although the diagnosis in individuals with mild CEP and HEP is readily mistaken for VP, HCP, and PCT during clinical evaluation, these erythropoietic porphyrias are differentiated particularly by finding high levels of erythrocyte porphyrins.</div></li><li class="half_rhythm"><div>Pseudoporphyria is a little-understood condition with cutaneous findings similar to PCT and VP but without significant porphyrin elevations.</div></li></ul></div><div id="porphyria-var.Management"><h2 id="_porphyria-var_Management_">Management</h2><div id="porphyria-var.Evaluations_Following_Init"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and to plan the management of an individual diagnosed with variegate porphyria (VP), the following clinical and laboratory evaluations (if not performed as part of the evaluation that led to the diagnosis) are recommended:</p><ul><li class="half_rhythm"><div>Degree of elevations on plasma and urine porphyrins and urine porphobilinogen (PBG), if not determined at the time of diagnosis</div></li><li class="half_rhythm"><div>Clinical evaluation of any current acute neurovisceral manifestations to determine the need for hospital admission and treatment with hemin.</div></li><li class="half_rhythm"><div>Nervous system. Assessment of the extent of neurologic involvement causing paresis, pain or sensory changes</div></li><li class="half_rhythm"><div>Psychiatric evaluation if depression or other psychiatric features are present</div></li><li class="half_rhythm"><div>Liver. Liver function tests to indicate chronic liver involvement and liver imaging in patients older than age 50 years</div></li><li class="half_rhythm"><div>Kidneys. Kidney function tests to assess for presence and progression of kidney damage</div></li><li class="half_rhythm"><div>Skin. Assessment of blistering cutaneous lesions to assess their relationship to VP</div></li><li class="half_rhythm"><div>Contributions of medications (see <a href="#porphyria-var.AgentsCircumstances_to_Avo">Agents/Circumstances to Avoid</a>), diet, and concurrent conditions to severity of VP</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="porphyria-var.Treatment_of_Manifestation"><h3>Treatment of Manifestations</h3><div id="porphyria-var.Neurovisceral_Symptoms"><h4>Neurovisceral Symptoms</h4><p>Most acute neurovisceral attacks require hospital admission; patients with mild attacks (not requiring narcotic analgesics and without hyponatremia, seizures, or muscle weakness) are sometimes treated as outpatients. A rapid, thorough, and multidisciplinary evaluation is optimized by in-patient management.</p><p>As with other acute porphyrias, evaluation should include identification of exacerbating drugs and other precipitating factors. Harmful medications include barbiturates, sulfonamide antibiotics, griseofulvin, rifampin, most anticonvulsants including phenytoin and carbamazepine, alcohol, ergot alkaloids, metoclopramide, and progestins. Harmful medications should be discontinued [<a class="bk_pop" href="#porphyria-var.REF.balwani.2017.1314">Balwani et al 2017</a>].</p><p>Seizures, motor neuropathy, and hyponatremia suggest severe disease and should be managed in the ICU with adequate supportive treatment. Evidence of reversible cerebral vasospasm may be found by MRI [<a class="bk_pop" href="#porphyria-var.REF.webb.2016.102">Webb et al 2016</a>].</p><p>Narcotic analgesics are usually required for pain and ondansetron or a related drug for nausea and vomiting. A phenothiazine is also effective for nausea and for psychiatric symptoms (e.g., agitation, hallucinations) [<a class="bk_pop" href="#porphyria-var.REF.anderson.2005.439">Anderson et al 2005</a>, <a class="bk_pop" href="#porphyria-var.REF.harper.2007.444">Harper &#x00026; Wahlin 2007</a>].</p><p>Mild attacks (not requiring narcotics and without hyponatremia, seizures, or motor neuropathy) can be treated with glucose loading, but most attacks should be treated with intravenous hemin [<a class="bk_pop" href="#porphyria-var.REF.anderson.2005.439">Anderson et al 2005</a>, <a class="bk_pop" href="#porphyria-var.REF.balwani.2017.1314">Balwani et al 2017</a>].</p><p>Note: "Hemin" refers to the oxidized form of iron protoporphyrin IX, but is also the generic term for heme preparations used as intravenous therapies for acute porphyrias, such as lyophilized hematin (heme hydroxide) and heme arginate. When these hemin preparations are infused intravenously, the heme is bound to circulating albumin as heme albumin. The latter is taken up by hepatocytes and decreases the synthesis of hepatic ALAS1, the rate-controlling enzyme for heme synthesis in the liver.</p><p>Patients with acute attack should be carefully monitored for muscle weakness and respiratory impairment that may require ventilatory support.</p><p>Hyponatremia should be corrected slowly and seizures treated with medications that do not exacerbate porphyria.</p><p>Liver transplantation, which has been effective in persons with <a href="/books/n/gene/aip/">acute intermittent porphyria</a> with severe repeated acute attacks that respond poorly to medical therapy, is also a consideration in VP [<a class="bk_pop" href="#porphyria-var.REF.dowman.2012.195">Dowman et al 2012</a>].</p><p>Progression of renal disease may be prevented to some degree by controlling hypertension.</p></div><div id="porphyria-var.Cutaneous_Manifestations"><h4>Cutaneous Manifestations</h4><p>Porphyrin levels may decrease and photosensitivity improve if exacerbating factors can be identified and removed; otherwise, there is no effective treatment that lowers porphyrin levels. Treatment with hemin may lower porphyrins in the short term only.</p><p>Patients should wear protective clothing and avoid exposure to sunlight.</p><p>Analgesics may be needed for painful lesions and antibiotics for superimposed infection. Topical steroids are of little or no benefit.</p><p>Specific measures effective in the treatment of <a href="/books/n/gene/porphyria-ct/">porphyria cutanea tarda</a> (i.e., phlebotomy and low-dose hydroxychloroquine or chloroquine) are not effective in the management of VP.</p></div></div><div id="porphyria-var.Prevention_of_Primary_Mani"><h3>Prevention of Primary Manifestations</h3><p><b>Acute attack</b></p><ul><li class="half_rhythm"><div>Attacks are less likely to occur in the future if exacerbating factors are corrected or avoided (see <a href="#porphyria-var.AgentsCircumstances_to_Avo">Agents/Circumstances to Avoid</a>).</div></li><li class="half_rhythm"><div>Recurrent premenstrual attacks of acute porphyrias, including VP, can be prevented with gonadotropin-releasing hormone analogs [<a class="bk_pop" href="#porphyria-var.REF.anderson.1990.1469">Anderson et al 1990</a>, <a class="bk_pop" href="#porphyria-var.REF.schulenburgbrand.2017.99">Schulenburg-Brand et al 2017</a>].</div></li><li class="half_rhythm"><div>Weekly or biweekly hemin infusions may prevent frequent noncyclical attacks; however, published experience is lacking [<a class="bk_pop" href="#porphyria-var.REF.marsden.2015.57">Marsden et al 2015</a>].</div></li><li class="half_rhythm"><div>Givosiran, a small interfering RNA (siRNA) therapeutic, was recently approved by the FDA for treatment of acute porphyrias, including VP. In particular, monthly subcutaneous injections of givosiran can be effective for prevention of frequently recurring attacks [<a class="bk_pop" href="#porphyria-var.REF.sardh.2019.549">Sardh et al 2019</a>].</div></li></ul><p><b>Photocutaneous manifestations.</b> Prevention of the skin manifestations of VP requires protection from sunlight. Avoidance of exacerbating factors may also be beneficial.</p></div><div id="porphyria-var.Surveillance"><h3>Surveillance</h3><p>Hepatocellular carcinoma may develop especially after age 50 years in patients with acute porphyrias and persistent elevations in porphobilinogen or porphyrins; liver imaging at six-month intervals beginning at age 50 years may detect early lesions [<a class="bk_pop" href="#porphyria-var.REF.andant.2000.933">Andant et al 2000</a>, <a class="bk_pop" href="#porphyria-var.REF.schneideryin.2010.512">Schneider-Yin et al 2010</a>].</p></div><div id="porphyria-var.AgentsCircumstances_to_Avo"><h3>Agents/Circumstances to Avoid</h3><p>Precipitating factors that should be avoided include: barbiturates, sulfonamide antibiotics, griseofulvin, rifampin, most anticonvulsants including phenytoin and carbamazepine, alcohol, ergot alkaloids, metoclopramide, and progestins.</p><p>Updated lists are maintained at the websites of the <a href="http://www.porphyriafoundation.com/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">American Porphyria Foundation</a> and the <a href="http://www.porphyria-europe.com/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">European Porphyria Network</a>.</p><p>Although birth control pills should generally be avoided, low-dose hormonal preparations may be tolerated.</p><p>Fasting and very low calorie diets should be avoided. Bariatric surgery should be avoided in patients who have had frequent exacerbations of VP and other acute porphyrias. Patients who wish to lose weight should do so gradually with moderate, long-term reductions in calorie intake under guidance of a dietician.</p></div><div id="porphyria-var.Evaluation_of_Relatives_at"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to clarify the genetic status of apparently asymptomatic older and younger at-risk relatives of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>. This will identify individuals <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> <i>PPOX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> who may benefit from counseling regarding appropriate use of drugs and avoidance of known precipitating factors.</p><p>See <a href="#porphyria-var.Related_Genetic_Counseling">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="porphyria-var.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Pregnancy is usually well tolerated in women with variegate porphyria (VP); however, some women with VP may experience exacerbations during pregnancy.</p><p><a class="bk_pop" href="#porphyria-var.REF.badminton.2006.668">Badminton &#x00026; Deybach [2006]</a> published an anecdotal report of successful treatment of several pregnant women experiencing attacks of VP or other acute porphyrias during pregnancy with hemin (in the form of heme arginate) without adverse fetal effect. They emphasize that interruption of pregnancy is almost never indicated for management of acute porphyria.</p><p>Experience with heme hydroxide (hematin) is also limited but suggests no adverse effects during pregnancy [<a class="bk_pop" href="#porphyria-var.REF.isenschmid.1992.1741">Isenschmid et al 1992</a>]. As noted (see Treatment of Manifestations, <a href="#porphyria-var.Neurovisceral_Symptoms">Neurovisceral Symptoms</a>), hemin is delivered to tissues as heme albumin when administered as either heme arginate or heme hydroxide, and these preparations are expected to have similar safety profiles.</p><p>A fetus <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>PPOX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has a good prognosis, because current postnatal management involves counseling the family regarding appropriate use of drugs and avoidance of known precipitating factors.</p><p>See <a href="http://www.mothertobaby.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MotherToBaby</a> for further information on medication use during pregnancy.</p></div><div id="porphyria-var.Therapies_Under_Investigat"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="porphyria-var.Genetic_Counseling"><h2 id="_porphyria-var_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="porphyria-var.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Variegate porphyria (VP) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner with reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>.</p></div><div id="porphyria-var.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Typically, one parent of an individual diagnosed with VP is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the <i>PPOX</i> pathogenic identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> and may or may not have had symptoms.</div></li><li class="half_rhythm"><div>Rarely, an individual diagnosed with VP may have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>Molecular genetic testing is recommended for the parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent. Though theoretically possible, no instances of a proband inheriting a pathogenic variant from a parent with germline mosaicism have been reported.</div></li><li class="half_rhythm"><div>The family history of some individuals diagnosed with VP may appear to be negative because of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> or failure to recognize the disorder as the cause of nonspecific symptoms in family members. Therefore, an apparently negative family history cannot be confirmed unless <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has been performed on the parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the sibs of the proband depends on the genetic status of the proband's parents:</p><ul><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has the <i>PPOX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in the proband, each sib has a 50% chance of inheriting the variant. A sib who inherits the pathogenic variant may or may not develop symptoms of VP.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a known VP-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> that cannot be detected in the leukocyte DNA of either parent, the <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> to sibs is estimated to be 1% because of the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> [<a class="bk_pop" href="#porphyria-var.REF.rahbari.2016.126">Rahbari et al 2016</a>].</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Each child of an individual with VP has a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>Offspring who inherit the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> may or may not develop symptoms.</div></li></ul><p><b>Other family members</b></p><ul><li class="half_rhythm"><div>The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent has the <i>PPOX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members may be at risk.</div></li><li class="half_rhythm"><div>A family member with the <i>PPOX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> may or may not develop symptoms of VP.</div></li></ul></div><div id="porphyria-var.Related_Genetic_Counseling"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#porphyria-var.Evaluation_of_Relatives_at">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition has the pathogenic variant identified in the proband or clinical evidence of the disorder, the pathogenic variant is likely <i>de novo</i>. However, non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="porphyria-var.Prenatal_Testing_and_Preim"><h3>Prenatal Testing and Preimplantation Genetic Testing</h3><p>Once the <i>PPOX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-testing/">preimplantation genetic testing</a> for VP are possible. Note: The presence of a <i>PPOX</i> pathogenic variant detected by prenatal testing does not predict whether individuals will be symptomatic, or if they are, the age of onset or presentation of the disorder.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="porphyria-var.Resources"><h2 id="_porphyria-var_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>American Porphyria Foundation (APF)</b></div><div>4915 St. Elmo Avenue</div><div>Suite 200</div><div>Bethesda MD 20814</div><div><b>Phone:</b> 1-866-APF-3635 (toll-free); 301-347-7166</div><div><b>Email:</b> porphyrus@porphyriafoundation.com</div><div><a href="https://www.porphyriafoundation.org/for-patients/types-of-porphyria/vp/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variegate Porphyria</a></div></li><li class="half_rhythm"><div><b>British &#x00026; Irish Porphyria Network (BIPNET)</b></div><div>United Kingdom</div><div><a href="http://www.bipnet.org.uk/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.bipnet.org.uk</a></div></li><li class="half_rhythm"><div><b>British Porphyria Association</b></div><div>United Kingdom</div><div><b>Phone:</b> 0300 30 200 30</div><div><b>Email:</b> helpline@porphyria.org.uk</div><div><a href="http://www.porphyria.org.uk/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.porphyria.org.uk</a></div></li><li class="half_rhythm"><div><b>Canadian Association for Porphyria/Association Canadienne de Porphyrie</b></div><div>Canada</div><div><a href="http://canadianassociationforporphyria.ca/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.canadianassociationforporphyria.ca</a></div></li><li class="half_rhythm"><div><b>Find a Porphyria Expert</b></div><div>American Porphyria Foundation</div><div><a href="https://www.porphyriafoundation.org/for-patients/porphyria-experts/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.porphyriafoundation.org/for-patients/porphyria-experts</a></div></li><li class="half_rhythm"><div><b>National Acute Porphyria Service (NAPS)</b></div><div>United Kingdom</div><div><b>Phone:</b> +44 29 2184 7747</div><div><a href="http://www.cardiffandvaleuhb.wales.nhs.uk/national-acute-porphyria-service-naps" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cardiffandvaleuhb.wales.nhs.uk/national-acute-porphyria-service-naps</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=variegateporphyria" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variegate porphyria</a></div></li><li class="half_rhythm"><div><b>Porphyria South Africa</b></div><div>South Africa</div><div><b>Phone:</b> +27 21-4066332</div><div><b>Fax:</b> +27 21-4066061</div><div><b>Email:</b> Peter.Meissner@uct.ac.za</div><div><a href="http://www.porphyria-patients.uct.ac.za/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Porphyria for Patients</a></div></li><li class="half_rhythm"><div><b>Welsh Medicines Information Centre</b></div><div><i>The Welsh Medicines Information Centre (WMIC) offers a specialist advisory service on the safe use of drugs in porphyria.</i></div><div>United Kingdom</div><div><b>Phone:</b> +44 029 2074 4298</div><div><a href="https://www.wmic.wales.nhs.uk/specialist-services/drugs-in-porphyria/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Drugs in Porphyria</a></div></li><li class="half_rhythm"><div><b>European Porphyria Network</b></div><div><b>Email:</b> contact@porphyria.eu</div><div><a href="http://porphyria.eu/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">porphyria.eu</a></div></li><li class="half_rhythm"><div><b>Swedish Porphyria Patients' Association</b></div><div>Karolinska Universitetssjukhuset</div><div>Huddinge M 96</div><div>Stockholm Stockholms Lan SE-141 86</div><div>Sweden</div><div><b>Phone:</b> +46 8 711 56 09 </div><div><b>Email:</b> porfyrisjukdomar@gmail.com</div><div><a href="http://www.porfyri.se" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.porfyri.se</a></div></li></ul></div><div id="porphyria-var.Molecular_Genetics"><h2 id="_porphyria-var_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="porphyria-var.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Variegate Porphyria: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK121283/table/porphyria-var.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__porphyria-var.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_porphyria-var.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_porphyria-var.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_porphyria-var.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_porphyria-var.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_porphyria-var.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_porphyria-var.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_porphyria-var.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/5498" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>PPOX</i></a></td><td headers="hd_b_porphyria-var.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=5498" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">1q23<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_porphyria-var.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P50336" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Protoporphyrinogen oxidase</a></td><td headers="hd_b_porphyria-var.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/PPOX" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PPOX database</a></td><td headers="hd_b_porphyria-var.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=PPOX" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PPOX</a></td><td headers="hd_b_porphyria-var.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=PPOX[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PPOX</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="porphyria-var.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="porphyria-var.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Variegate Porphyria (<a href="/omim/176200,600923" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK121283/table/porphyria-var.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__porphyria-var.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/176200" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">176200</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VARIEGATE PORPHYRIA; VP</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/600923" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">600923</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PROTOPORPHYRINOGEN OXIDASE; PPOX</td></tr></tbody></table></div></div><div id="porphyria-var.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>PPOX catalyzes the oxidation of protoporphyrinogen to protoporphyrin, with removal of six protons. The partial deficiency of PPOX in VP limits heme synthesis, particularly in the presence of factors that lead to increased hepatic heme synthesis and induction of &#x003b4;-aminolevulinic acid synthase-1 (ALAS1) in the liver. ALAS1 is the ubiquitous form of ALAS, which is found in all tissues, in contrast to the erythroid-specific form known as ALAS2, which is produced only in the bone marrow.</p><p><b>Mechanism of disease causation.</b> VP is caused by <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> <i>PPOX</i> variants, resulting in reduction of the enzyme in all tissues to approximately 50% of normal.</p><div id="porphyria-var.T.notable_ppox_pathogenic" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Notable <i>PPOX</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK121283/table/porphyria-var.T.notable_ppox_pathogenic/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__porphyria-var.T.notable_ppox_pathogenic_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_porphyria-var.T.notable_ppox_pathogenic_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th><th id="hd_h_porphyria-var.T.notable_ppox_pathogenic_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_porphyria-var.T.notable_ppox_pathogenic_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_porphyria-var.T.notable_ppox_pathogenic_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment [Reference]</th></tr></thead><tbody><tr><td headers="hd_h_porphyria-var.T.notable_ppox_pathogenic_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_001122764.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_001122764<wbr style="display:inline-block"></wbr>​.1</a><br /><a href="/protein/NP_001116236.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_001116236<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_h_porphyria-var.T.notable_ppox_pathogenic_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.175C&#x0003e;T</td><td headers="hd_h_porphyria-var.T.notable_ppox_pathogenic_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg59Trp</td><td headers="hd_h_porphyria-var.T.notable_ppox_pathogenic_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Founder variant in the Afrikaner population of South Africa, in which it accounts for ~95% of VP [<a class="bk_pop" href="#porphyria-var.REF.dean.1971">Dean 1971</a>, <a class="bk_pop" href="#porphyria-var.REF.meissner.1996.95">Meissner et al 1996</a>]</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div></div></div><div id="porphyria-var.References"><h2 id="_porphyria-var_References_">References</h2><div id="porphyria-var.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="porphyria-var.REF.andant.2000.933">Andant C, Puy H, Bogard C, Faivre J, Soul&#x000e9; JC, Nordmann Y, Deybach JC. Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. <span><span class="ref-journal">J Hepatol. </span>2000;<span class="ref-vol">32</span>:933–9.</span> [<a href="/pubmed/10898313" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10898313</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-var.REF.anderson.2005.439">Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR, Desnick RJ. Recommendations for the diagnosis and treatment of the acute porphyrias. <span><span class="ref-journal">Ann Intern Med. </span>2005;<span class="ref-vol">142</span>:439–50.</span> [<a href="/pubmed/15767622" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15767622</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-var.REF.anderson.1990.1469">Anderson KE, Spitz IM, Bardin CW, Kappas A. A gonadotropin releasing hormone analogue prevents cyclical attacks of porphyria. <span><span class="ref-journal">Arch Intern Med. </span>1990;<span class="ref-vol">150</span>:1469–74.</span> [<a href="/pubmed/2196028" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2196028</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-var.REF.badminton.2006.668">Badminton MN, Deybach JC. Treatment of an acute attack of porphyria during pregnancy. <span><span class="ref-journal">Eur J Neurol. </span>2006;<span class="ref-vol">13</span>:668–9.</span> [<a href="/pubmed/16796597" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16796597</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-var.REF.balwani.2017.1314">Balwani M, Wang B, Anderson KE, Bloomer JR, Bissell DM, Bonkovsky HL, Phillips JD, Desnick RJ. Acute hepatic porphyrias: recommendations for evaluation and long-term management. <span><span class="ref-journal">Hepatology. </span>2017;<span class="ref-vol">66</span>:1314–1322.</span> [<a href="/pmc/articles/PMC5605422/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5605422</span></a>] [<a href="/pubmed/28605040" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28605040</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-var.REF.barbaro.2013.13">Barbaro M, Kotaj&#x000e4;rvi M, Harper P, Floderus Y. Partial protoporphyrinogen oxidase (PPOX) gene deletions, due to different Alu-mediated mechanisms, identified by MLPA analysis in patients with variegate porphyria. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2013;<span class="ref-vol">8</span>:13.</span> [<a href="/pmc/articles/PMC3554555/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3554555</span></a>] [<a href="/pubmed/23324528" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23324528</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-var.REF.dean.1971">Dean G. <em>The Porphyrias: A Study of Inheritance and Environment</em>. 2 ed. London, UK: Pitman Medical; 1971.</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-var.REF.dowman.2012.195">Dowman JK, Gunson BK, Mirza DF, Bramhall SR, Badminton MN, Newsome PN, et al.  Liver transplantation for acute intermittent porphyria is complicated by a high rate of hepatic artery thrombosis. <span><span class="ref-journal">Liver Transpl. </span>2012;<span class="ref-vol">18</span>:195–200.</span> [<a href="/pmc/articles/PMC3472026/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3472026</span></a>] [<a href="/pubmed/21618697" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21618697</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-var.REF.elder.2013.849">Elder G, Pauline Harper P, Michael Badminton M, Sandberg S, Deybach J-C. The incidence of inherited porphyrias in Europe. <span><span class="ref-journal">J Inherit Metab Dis. </span>2013;<span class="ref-vol">36</span>:849–57.</span> [<a href="/pubmed/23114748" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23114748</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-var.REF.frank.1998.452">Frank J, McGrath J, Lam H, Graham RM, Hawk JL, Christiano AM. Homozygous variegate porphyria: identification of mutations on both alleles of the protoporphyrinogen oxidase gene in a severely affected proband. <span><span class="ref-journal">J Invest Dermatol. </span>1998;<span class="ref-vol">110</span>:452–5.</span> [<a href="/pubmed/9540991" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9540991</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-var.REF.harper.2007.444">Harper P, Wahlin S. Treatment options in acute porphyria, porphyria cutanea tarda, and erythropoietic protoporphyria. <span><span class="ref-journal">Curr Treat Options Gastroenterol. </span>2007;<span class="ref-vol">10</span>:444–55.</span> [<a href="/pubmed/18221605" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18221605</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-var.REF.hift.2005.48">Hift RJ, Meissner PN. An analysis of 112 acute porphyric attacks in Cape Town, South Africa: Evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity. <span><span class="ref-journal">Medicine (Baltimore). </span>2005;<span class="ref-vol">84</span>:48–60.</span> [<a href="/pubmed/15643299" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15643299</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-var.REF.isenschmid.1992.1741">Isenschmid M, K&#x000f6;nig C, F&#x000e4;ssli C, Haenel A, H&#x000e4;nggi W, Schneider H. Acute intermittent porphyria in pregnancy: glucose or hematin therapy? <span><span class="ref-journal">Schweiz Med Wochenschr. </span>1992;<span class="ref-vol">122</span>:1741–5.</span> [<a href="/pubmed/1448679" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1448679</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-var.REF.kauppinen.1992.1">Kauppinen R, Mustajoki P. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. <span><span class="ref-journal">Medicine (Baltimore). </span>1992;<span class="ref-vol">71</span>:1–13.</span> [<a href="/pubmed/1549056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1549056</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-var.REF.marsden.2015.57">Marsden JT, Guppy S, Stein P, Cox TM, Badminton M, Gardiner T, Barth JH, Stewart MF, Rees DC. Audit of the use of regular haem arginate Infusions in patients with acute porphyria to prevent recurrent symptoms. <span><span class="ref-journal">JIMD Reports. </span>2015;<span class="ref-vol">22</span>:57–65.</span> [<a href="/pmc/articles/PMC4486272/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4486272</span></a>] [<a href="/pubmed/25762493" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25762493</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-var.REF.mauzerall.1956.435">Mauzerall D, Granick S. The occurrence and determination of &#x003b4;-aminolevulinic acid and porphobilinogen in urine. <span><span class="ref-journal">J Biol Chem. </span>1956;<span class="ref-vol">219</span>:435–46.</span> [<a href="/pubmed/13295297" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13295297</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-var.REF.meissner.2003">Meissner P, Hift RJ, Corrigall A. Variegate porphyria. In: Kadish KM, Smith K, Guilard R, eds. <em>Porphyrin Handbook, Part II</em>. Vol 14. San Diego, CA: Academic Press; 2003:93-120.</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-var.REF.meissner.1996.95">Meissner PN, Dailey TA, Hift RJ, Ziman M, Corrigall AV, Roberts AG, Meissner DM, Kirsch RE, Dailey HA. A. R59W mutation in human protoporphyrinogen oxidase results in decreased enzyme activity and is prevalent in South Africans with variegate porphyria. <span><span class="ref-journal">Nat Genet. </span>1996;<span class="ref-vol">13</span>:95–7.</span> [<a href="/pubmed/8673113" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8673113</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-var.REF.peters.2011.261">Peters T. King George III, bipolar disorder, porphyria and lessons for historians. <span><span class="ref-journal">Clin Med (Lond). </span>2011;<span class="ref-vol">11</span>:261–4.</span> [<a href="/pmc/articles/PMC4953321/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4953321</span></a>] [<a href="/pubmed/21902081" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21902081</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-var.REF.pinder.2013.737">Pinder VA, Holden ST, Deshpande C, Siddiqui A, Mellerio JE, Wraige E, Powell AM. Homozygous variegate porphyria presenting with developmental and language delay in childhood. <span><span class="ref-journal">Clin Exp Dermatol. </span>2013;<span class="ref-vol">38</span>:737–40.</span> [<a href="/pubmed/24073655" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24073655</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-var.REF.pohfitzpatrick.1980.543">Poh-Fitzpatrick MB. A plasma porphyrin fluorescence marker for variegate porphyria. <span><span class="ref-journal">Arch Dermatol. </span>1980;<span class="ref-vol">116</span>:543–7.</span> [<a href="/pubmed/7377785" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7377785</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-var.REF.rahbari.2016.126">Rahbari R, Wuster A, Lindsay SJ, Hardwick RJ, Alexandrov LB, Turki SA, Dominiczak A, Morris A, Porteous D, Smith B, Stratton MR, Hurles ME, et al.  Timing, rates and spectra of human germline mutation. <span><span class="ref-journal">Nat Genet. </span>2016;<span class="ref-vol">48</span>:126–33.</span> [<a href="/pmc/articles/PMC4731925/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4731925</span></a>] [<a href="/pubmed/26656846" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26656846</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-var.REF.sardh.2019.549">Sardh E, Harper P, Balwani B, Stein P, Rees D, Bissell DM, Desnick R, Parker C, Phillips J, Bonkovsky HL, Vassiliou D, Penz C, Chan-Daniels A, He Q, Querbes W, Fitzgerald K, Kim JB. MD, Garg P, Vaishnaw A, Simon AR, Anderson KE, A phase 1 study of RNA interference therapy for acute intermittent porphyria. <span><span class="ref-journal">NEJM. </span>2019;<span class="ref-vol">380</span>:549–58.</span> [<a href="/pubmed/30726693" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30726693</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-var.REF.schneideryin.2010.512">Schneider-Yin X, van Tuyll van Serooskerken AM, Went P, Tyblewski W, Poblete-Guti&#x000e9;rrez P, Minder EI, Frank J. Hepatocellular carcinoma in variegate porphyria: a serious complication. <span><span class="ref-journal">Acta Derm Venereol. </span>2010;<span class="ref-vol">90</span>:512–5.</span> [<a href="/pubmed/20814629" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20814629</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-var.REF.schulenburgbrand.2017.99">Schulenburg-Brand D, Gardiner T, Guppy S, Rees DC, Stein P, Barth J, Stewart MF, Badminton M. An audit of the use of gonadorelin analogues to prevent recurrent acute symptoms in patients with acute porphyria in the United Kingdom. <span><span class="ref-journal">JIMD Reports. </span>2017;<span class="ref-vol">36</span>:99–107.</span> [<a href="/pmc/articles/PMC5680288/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5680288</span></a>] [<a href="/pubmed/28220410" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28220410</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-var.REF.van_tuyll_van_serooskerken.2011.2249">van Tuyll van Serooskerken AM, de Rooij FW, Edixhoven A, Bladergroen RS, Baron JM, Joussen S, Merk HF, Steijlen PM, Poblete-Guti&#x000e9;rrez P, te Velde K, Wilson JH, Koole RH, van Geel M, Frank J. Digenic inheritance of mutations in the coproporphyrinogen oxidase and protoporphyrinogen oxidase genes in a unique type of porphyria. <span><span class="ref-journal">J Invest Dermatol. </span>2011;<span class="ref-vol">131</span>:2249–54.</span> [<a href="/pubmed/21734717" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21734717</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-var.REF.webb.2016.102">Webb AJS, Ingale H, Irani SR, Hu MTM. Acute variegate porphyria presenting with reversible cerebral vasoconstriction. <span><span class="ref-journal">Clin Neurol Neurosurg. </span>2016;<span class="ref-vol">146</span>:102–4.</span> [<a href="/pubmed/27186968" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27186968</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-var.REF.whatley.2009.1406">Whatley SD, Mason NG, Woolf JR, Newcombe RG, Elder GH, Badminton MN. Diagnostic strategies for autosomal dominant acute porphyrias: retrospective analysis of 467 unrelated patients referred for mutational analysis of the HMBS, CPOX, or PPOX gene. <span><span class="ref-journal">Clin Chem. </span>2009;<span class="ref-vol">55</span>:1406–14.</span> [<a href="/pubmed/19460837" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19460837</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-var.REF.whatley.1999.984">Whatley SD, Puy H, Morgan RR, Robreau AM, Roberts AG, Nordmann Y, Elder GH, Deybach JC. Variegate porphyria in Western Europe: identification of PPOX gene mutations in 104 families, extent of allelic heterogeneity, and absence of correlation between phenotype and type of mutation. <span><span class="ref-journal">Am J Hum Genet. </span>1999;<span class="ref-vol">65</span>:984–94.</span> [<a href="/pmc/articles/PMC1288269/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1288269</span></a>] [<a href="/pubmed/10486317" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10486317</span></a>]</div></li></ul></div></div><div id="porphyria-var.Chapter_Notes"><h2 id="_porphyria-var_Chapter_Notes_">Chapter Notes</h2><div id="porphyria-var.Acknowledgments"><h3>Acknowledgments</h3><p>This work is supported by the Porphyrias Consortium funded by the NIH/NIDDK and part of the Rare Diseases Clinical Research Network, and the American Porphyria Foundation.</p></div><div id="porphyria-var.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>12 December 2019 (bp) Comprehensive update posted live</div></li><li class="half_rhythm"><div>14 February 2013 (me) Review posted live</div></li><li class="half_rhythm"><div>12 June 2012 (kea) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK121283</span><span class="label">PMID: <a href="/pubmed/23409300" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">23409300</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/vps35-pd/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/eds4/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK121283&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK121283/?report=reader">PubReader</a></li><li><a href="/books/NBK121283/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK121283" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK121283" style="display:none" title="Cite this Page"><div class="bk_tt">Singal AK, Anderson KE. Variegate Porphyria. 2013 Feb 14 [Updated 2019 Dec 12]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK121283/pdf/Bookshelf_NBK121283.pdf">PDF version of this page</a> (522K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#porphyria-var.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#porphyria-var.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#porphyria-var.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#porphyria-var.Genetically_Related_Alleli" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#porphyria-var.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#porphyria-var.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#porphyria-var.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#porphyria-var.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#porphyria-var.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#porphyria-var.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#porphyria-var.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5498[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">PPOX</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3077[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">HFE</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK121283+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=3011808" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=3011808" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=3011808" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=3011808" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301372" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Acute Intermittent Porphyria</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Acute Intermittent Porphyria<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Whatley SD, Badminton MN. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23236641" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hereditary Coproporphyria</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hereditary Coproporphyria<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wang B, Bissell DM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301512" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hypokalemic Periodic Paralysis</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hypokalemic Periodic Paralysis<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Weber F, Lehmann-Horn F. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24027798" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital Erythropoietic Porphyria</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital Erythropoietic Porphyria<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Erwin A, Balwani M, Desnick RJ, Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23741761" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Familial Porphyria Cutanea Tarda</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Familial Porphyria Cutanea Tarda<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Liu LU, Phillips J, Bonkovsky H, Porphyrias Consortium of the Rare Diseases Clinical Research Network. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=23409300" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=23409300" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040e6475f66d18aaaa838d">Variegate Porphyria - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Variegate Porphyria - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:35:32-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal103&amp;ncbi_phid=CE8A3525E040874100000000025F00C8&amp;ncbi_session=CE8A3525E040E641_0607SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK121283%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK121283&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK121283/&amp;ncbi_pagename=Variegate Porphyria - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8A3525E040E641_0607SID /projects/books/PBooks@5.22 portal103 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>